Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial.

Dossier C, Sellier-Leclerc AL, Simon T, Parmentier C, Boyer O, Samaille C, Fila M, Roussey-Kesler G, Magnavacca M, Chartier Y, Louillet F, Zaloszyc A, Vrillon I, Elaribi D, Bouatia S, Kaguelidou F, Guilmin-Crepon S, Hogan J

Open source

DOI: 10.1136/bmjopen-2025-111980
Published: 2025 Dec 24
Container: BMJ open
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2025-111980,
  title = {Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial.},
  author = {Dossier C and Sellier-Leclerc AL and Simon T and Parmentier C and Boyer O and Samaille C and Fila M and Roussey-Kesler G and Magnavacca M and Chartier Y and Louillet F and Zaloszyc A and Vrillon I and Elaribi D and Bouatia S and Kaguelidou F and Guilmin-Crepon S and Hogan J},
  year = {2025},
  journal = {BMJ open},
  doi = {10.1136/bmjopen-2025-111980},
  url = {https://doi.org/10.1136/bmjopen-2025-111980}
}

RIS

TY  - JOUR
TI  - Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial.
AU  - Dossier C
AU  - Sellier-Leclerc AL
AU  - Simon T
AU  - Parmentier C
AU  - Boyer O
AU  - Samaille C
AU  - Fila M
AU  - Roussey-Kesler G
AU  - Magnavacca M
AU  - Chartier Y
AU  - Louillet F
AU  - Zaloszyc A
AU  - Vrillon I
AU  - Elaribi D
AU  - Bouatia S
AU  - Kaguelidou F
AU  - Guilmin-Crepon S
AU  - Hogan J
PY  - 2025
JO  - BMJ open
DO  - 10.1136/bmjopen-2025-111980
UR  - https://doi.org/10.1136/bmjopen-2025-111980
ER  -

APA

C, D., AL, S., T, S., C, P., O, B., C, S., M, F., G, R., M, M., Y, C., F, L., A, Z., I, V., D, E., S, B., F, K., S, G., & J, H. (2025). Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial.. BMJ open. https://doi.org/10.1136/bmjopen-2025-111980

Source records

pubmed · retrieved 2026-09-26T22:12:42.163Z
europe-pmc · retrieved 2026-09-26T22:12:42.175Z
doaj · retrieved 2026-09-26T22:12:42.167Z
hal · retrieved 2026-09-26T22:12:42.192Z